8079例系统性硬化症患者血管药物使用的时间趋势:来自EUSTAR队列的启示以指导未来试验和治疗策略
基于EUSTAR数据库中符合2013年ACR/EULAR系统性硬化症分类标准的8079例患者,比较2012-2017年与2018-2022年两个时段的血管药物处方模式。结果显示内皮素受体拮抗剂、磷酸二酯酶5抑制剂、钙通道阻滞剂和抗血小板治疗使用增加,静脉伊洛前列素使用显著下降,活动性指端溃疡患病率下降而指端溃疡病史增加。
要点
- 内皮素受体拮抗剂使用从7%升至12%(P<0.001),钙通道阻滞剂从20%升至32%(P<0.001)。
- 磷酸二酯酶5抑制剂从5.4%升至7.2%(P=0.064),抗血小板治疗从15%升至20%(P<0.001)。
- 静脉伊洛前列素从3.1%降至0.3%(P<0.001),活动性指端溃疡从16%降至13%(P=0.040)。
核心结论
- 系统性硬化症患者血管药物使用随时间发生显著变化,内皮素受体拮抗剂、磷酸二酯酶5抑制剂、钙通道阻滞剂和抗血小板治疗使用增加,提示采用了更积极和/或预防性治疗策略。
研究设计与样本
- 横断面研究,纳入EUSTAR数据库中符合2013年ACR/EULAR系统性硬化症分类标准的患者,分为2012-2017年和2018-2022年两个时段,共8079例。
- 分析内皮素受体拮抗剂、磷酸二酯酶5抑制剂、钙通道阻滞剂、静脉伊洛前列素和抗血小板治疗的处方模式,采用逻辑回归评估时间趋势和交互效应。
主要发现
- 内皮素受体拮抗剂使用从7%升至12%(P<0.001),磷酸二酯酶5抑制剂从5.4%升至7.2%(P=0.064)。
- 钙通道阻滞剂使用从20%升至32%(P<0.001),抗血小板治疗从15%升至20%(P<0.001)。
- 静脉伊洛前列素使用从3.1%降至0.3%(P<0.001)。
- 活动性指端溃疡患病率从16%降至13%(P=0.040),指端溃疡病史从24%升至30%(P<0.001)。
- 内皮素受体拮抗剂和钙通道阻滞剂呈逐年及非线性增加,磷酸二酯酶5抑制剂呈非线性增加,伊洛前列素呈逐年及非线性下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Systemic sclerosis (SSc) is characterized by widespread vascular damage resulting in digital and systemic vasculopathic sequelae. Although there are effective treatments available, vascular disease remains a significant cause of morbidity and mortality in SSc. Our aim was to describe patterns of vascular medication use in SSc, including examination for potential changes over time. METHODS: A cross-sectional study of SSc patients enrolled in the EUSTAR database meeting 2013 ACR/EULAR SSc criteria. Patients were divided into two time periods: 2012-2017 and 2018-2022. We analysed the prescription patterns of endothelin receptor antagonists (ERA), phosphodiesterase type-5 inhibitors (PDE5i), calcium channel blockers (CCB), intravenous iloprost, and antiplatelet therapies. Logistic regression was used to evaluate temporal trends and interaction effects. RESULTS: A total of 8079 patients were included. Significant increases over time were observed in the use of ERA (7% to 12%, P < 0.001), PDE5i (5.4% to 7.2%, P = 0.064), CCB (20% to 32%, P < 0.001) and anti-platelet therapies (15% to 20%, P < 0.001). There was a notable decrease in iloprost use (3.1% to 0.3%, P < 0.001). The prevalence of active digital ulcers (DU) decreased (16% to 13%, P = 0.040), while a history of DU (24% to 30%, P < 0.001) increased. Year-by-year and non-linear increases were noted for ERA and CCB whereas non-linear increase was observed for PDE5i. Year-by-year and non-linear decrease was observed for Iloprost prescription. CONCLUSION: A significant change has occurred over time in vascular medication use in SSc patients, with increased utilization of ERA, PDE5i, CCB and anti-platelet therapies suggesting the adoption of more proactive and/or preventive treatment strategies.
引用
- Di Donato S, Pauling JD, Ramjug S, et al. Temporal trends in vascular medication use in 8079 patients with systemic sclerosis: insights to inform future trials and therapeutic strategies from the EUSTAR cohort. Rheumatology (Oxford). 2025. PMID: 40457784. doi:10.1093/rheumatology/keaf290
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。